PTGS2 and coronary artery disorder: The cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) is still under scrutiny after the introduction of selective cyclooxygenase-2 (COX-2) inhibitors.1–3 The United States (US) Food and Drug Administration and the European Medicines Agency reviewed the safety of selective COX-2 inhibitors, resulting in their contraindication in patients with ischemic heart disease, stroke, or peripheral arterial disease.